LYEL lyell.com: Enterprise Value to EBITDA Ratio

Graphic logo of Lyell Immunopharma, Inc. (LYEL)

The EV/EBITDA price visualization, with a value of 0.00, complements data on the creation of complex live-cell transport systems and a cryo-storage network to protect Lyell Immunopharma (LYEL) margins. Lyell Immunopharma (LYEL) is expanding the application of its T-cell developments, focusing on solid tumor therapies. The business is currently developing its own immune reprogramming platforms, limiting itself to clinical partnerships without engaging in merger and acquisition deals.

Lyell Immunopharma Inc - LYEL Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/17/2026)

Summary analytical data breakdowns for Lyell Immunopharma Inc (LYEL)

- stock price and consensus target price:
Fundamental company analysis:LYEL (Lyell Immunopharma, Inc.)
Original product of Lyell

To objectively measure the operational success of Lyell Immunopharma (LYEL), investors require a tool that eliminates subjective assessments. By analyzing the fluctuations in the company's EV/EBITDA ratio, you can see the relationship between enterprise value and earnings before interest, taxes, depreciation, and amortization. This indicator reveals the real value of assets, stripped of debt load. This is critical for evaluating the costs of ultra-precise biomaterial logistics, where supply chain efficiency directly impacts the issuer's fundamental value.

Competitor analysis for Lyell Immunopharma

ImmunityBio Inc - Enterprise Value to EBITDA Ratio|Immunocore (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (Arcus Biosciences)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iovance.com|Enterprise Value to EBITDA Ratio immatics.com (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor Inc (XNCR)|Enterprise Value to EBITDA Ratio Compass Bio CMPX|Replimune Group Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Innate Pharma S.A IPHA|PYXS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CGEN (Compugen) - Enterprise Value to Operating Income Before Depreciation|IO Biotech Inc. (IOBT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Sutro Bio (STRO)|Enterprise Value to EBITDA Ratio INKT|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma Inc.)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Bio|Liminatus Pharma (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics NV - Business Value to Operating Income Before Depreciation|NXTC (nextcure.com) - EV/EBITDA Multiple|EV/EBITDA Multiple leaptx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization intensitytherapeutics.com (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Theriva Biologics Inc - Enterprise Value to EBITDA Ratio|Gritstone Bio (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NEXI (NexImmune) - Enterprise Value to Operating Income Before Depreciation|TSBX (Turnstone Biologics Corp.) - Enterprise Value to EBITDA Ratio|Vaccinex, Inc (VCNX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Therapeutics